Intended for healthcare professionals

Rapid response to:

Analysis

Drugs for pre-osteoporosis: prevention or disease mongering?

BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39435.656250.AD (Published 17 January 2008) Cite this as: BMJ 2008;336:126

Rapid Response:

Excellent Paper

Gentlemen:

Congratulations on your excellent paper "Drugs for Pre-Osteoporosis:
Prevention or Disease Mongering "BMJ 2008:336:126-129. You are very
correct to expose the overt influence bisphsohonate drug companies have
had in the prescribing practices of physicians throughout the world and
how their drug company supported studies have messaged the data to
embelish results beyond real therapuetic value. As the oral and
maxillofacial surgoen who first described Bisphosphonate Induced
Osteonecrosis of the Jaws (BIONJ), 65% of our patients with such exposed
bone often with secondary infection were taking mostly alendronate for
"pre-osteoporosis".

If any of our data base is of interst to you, please do nto hesitate
to contact me at rmarx@med.miami.edu.

Sincerely,

Competing interests:
None declared

Competing interests: No competing interests

07 March 2008
Robert Marx
Professor of Surgery and Chief
9380 SW 150th Street, #170, Miami, FL 33176
University of Miami Miller School of Medicine